VivoSeq
Other

Intranasal Administration

0

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Intranasal Administration is an early-stage landscape with 0 programs across 3 companies. The most active players are Ceres Brain Therapeutics, Pharmenterprises Biotech LLC, GSK.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

86/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Ceres Brain Therapeutics

0 programs

PreclinicalP

Pharmenterprises Biotech LLC

0 programs

PreclinicalGSK logo

GSK

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

16

clinical trials

Completed12 · 75%
Unknown status1 · 6%
Recruiting1 · 6%
Withdrawn1 · 6%
Terminated1 · 6%

Clinical Trials

Trial Activity

16 trials

Intranasal Administration of Dodecyl Creatine Ester (CBT101) in Healthy Male Subjects
Recruiting·CCeres Brain Therapeutics·Phase 1·NCT07050316·48 enrolled
Intranasal Administration of a Prokinetic for Bowel Evacuation in Persons With SCI
Completed·US Department of Veterans Affairs·Phase 2·NCT00855283·20 enrolled
Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects
Completed·OOsivax·Phase 1·NCT03594890·72 enrolled
Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device
Completed·OOptinose US Inc.·Phase 3·NCT01624662·323 enrolled
Bioavailability of Dexmedetomidine After Intranasal Administration
Completed·UUniversity of Turku·Phase 1·NCT00837187·7 enrolled
Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers
Completed·—·Phase 2·NCT00748956·10 enrolled
Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Healthy Adults
Completed·OOptiNose AS·Phase 1·NCT01983514·19 enrolled
Study to Assess Safety, Tolerability and Reactogenicity of Vaccine "UniFluVec" After Two Intranasal Administrations in Healthy Volunteers
Completed·PPharmenterprises Biotech LLC·Phase 1·NCT04650971·60 enrolled
Study of the Tolerability of Ketorolac Tromethamine Following Intranasal Administration in Healthy Volunteers
Completed·EEgalet Ltd·Phase 1·NCT01363063·40 enrolled
A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2)
Completed·OOptinose US Inc.·Phase 1·NCT02266927·28 enrolled
A Study to Investigate the Safety and Pharmacodynamics of Repeat Intranasal Administration of the TLR7 Agonist GSK2245035 in Subjects With Respiratory Allergies
Completed·GSK logoGSK·Phase 2·NCT01607372·18 enrolled
Study to Determine the Tolerability, Safety and Pharmacokinetics of Ketorolac Tromethamine by Intranasal Administration in Healthy Volunteers
Completed·EEgalet Ltd·Phase 1·NCT01363050·15 enrolled
Tolerance of Intranasal Administration of OT in Prader-Willi Newborn Babies
Completed·UUniversity Hospital, Toulouse·Phase 1/2·NCT01548521·5 enrolled
Pharmacokinetics of Nalbuphine After Intravenous and Intranasal Administration in Infants
Terminated·UUniversity Children's Hospital, Zurich·Phase 1·NCT03059511·51 enrolled
To Test the Potential Efficacy of Repeated Intranasal Administration of Ketamine as a Treatment for PTSD
Withdrawn·—·Phase 2/3·NCT02398136
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)